Competition in Biofilms between Cystic Fibrosis Isolates of Pseudomonas aeruginosa Is Shaped by R-Pyocins

A major clinical problem caused by Pseudomonas aeruginosa, is chronic biofilm infection of the lungs in individuals with cystic fibrosis (CF). Epidemic P. aeruginosa strains dominate and displace others during CF infection, but these intraspecies interactions remain poorly understood. Here we demonstrate that R-pyocins (bacteriocins) are important factors in driving competitive interactions in biofilms between P. aeruginosa strains isolated from different CF patients. In addition, we found that these phage-like pyocins are inhibitory against mature biofilms of susceptible strains. This highlights the potential of R-pyocins as antimicrobial and antibiofilm agents at a time when new antimicrobial therapies are desperately needed. ABSTRACT Pseudomonas aeruginosa is an opportunistic pathogen and the leading cause of morbidity and mortality in cystic fibrosis (CF) patients. P. aeruginosa infections are difficult to treat due to a number of antibiotic resistance mechanisms and the organism’s propensity to form multicellular biofilms. Epidemic strains of P. aeruginosa often dominate within the lungs of individual CF patients, but how they achieve this is poorly understood. One way that strains of P. aeruginosa can compete is by producing chromosomally encoded bacteriocins, called pyocins. Three major classes of pyocin have been identified in P. aeruginosa: soluble pyocins (S types) and tailocins (R and F types). In this study, we investigated the distribution of S- and R-type pyocins in 24 clinical strains isolated from individual CF patients and then focused on understanding their roles in interstrain competition. We found that (i) each strain produced only one R-pyocin type, but the number of S-pyocins varied between strains, (ii) R-pyocins were generally important for strain dominance during competition assays in planktonic cultures and biofilm communities in strains with both disparate R- and S-pyocin subtypes, and (iii) purified R-pyocins demonstrated significant antimicrobial activity against established biofilms. Our work provides support for a role played by R-pyocins in the competition between P. aeruginosa strains and helps explain why certain strains and lineages of P. aeruginosa dominate and displace others during CF infection. Furthermore, we demonstrate the potential of exploiting R-pyocins for therapeutic gains in an era when antibiotic resistance is a global concern. IMPORTANCE A major clinical problem caused by Pseudomonas aeruginosa, is chronic biofilm infection of the lungs in individuals with cystic fibrosis (CF). Epidemic P. aeruginosa strains dominate and displace others during CF infection, but these intraspecies interactions remain poorly understood. Here we demonstrate that R-pyocins (bacteriocins) are important factors in driving competitive interactions in biofilms between P. aeruginosa strains isolated from different CF patients. In addition, we found that these phage-like pyocins are inhibitory against mature biofilms of susceptible strains. This highlights the potential of R-pyocins as antimicrobial and antibiofilm agents at a time when new antimicrobial therapies are desperately needed.

[1]  A. Oliver,et al.  Susceptibility to R-pyocins of Pseudomonas aeruginosa clinical isolates from cystic fibrosis patients , 2018, The Journal of antimicrobial chemotherapy.

[2]  D. Scholl Phage Tail-Like Bacteriocins. , 2017, Annual review of virology.

[3]  E. Nash,et al.  The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers , 2017, Thorax.

[4]  M. P. Mokoena Lactic Acid Bacteria and Their Bacteriocins: Classification, Biosynthesis and Applications against Uropathogens: A Mini-Review , 2017, Molecules.

[5]  Fengan Yu,et al.  Environmental Pseudomonads Inhibit Cystic Fibrosis Patient-Derived Pseudomonas aeruginosa , 2016, Applied and Environmental Microbiology.

[6]  I. Kukavica-Ibrulj,et al.  Temperate phages enhance pathogen fitness in chronic lung infection , 2016, The ISME Journal.

[7]  J. Kitzman,et al.  Regional Isolation Drives Bacterial Diversification within Cystic Fibrosis Lungs. , 2015, Cell host & microbe.

[8]  K. Foster,et al.  Biofilm Formation As a Response to Ecological Competition , 2015, PLoS biology.

[9]  M. Brockhurst,et al.  Divergent, coexisting Pseudomonas aeruginosa lineages in chronic cystic fibrosis lung infections. , 2015, American journal of respiratory and critical care medicine.

[10]  J. Corander,et al.  Recombination is a key driver of genomic and phenotypic diversity in a Pseudomonas aeruginosa population during cystic fibrosis infection , 2015, Scientific Reports.

[11]  G. Walker,et al.  Biological Cost of Pyocin Production during the SOS Response in Pseudomonas aeruginosa , 2014, Journal of bacteriology.

[12]  R. Rajendran,et al.  Activity of Pyocin S2 against Pseudomonas aeruginosa Biofilms , 2011, Antimicrobial Agents and Chemotherapy.

[13]  M. Brockhurst,et al.  Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections. , 2011, American journal of respiratory and critical care medicine.

[14]  Nazanin Saeidi,et al.  A predicted S‐type pyocin shows a bactericidal activity against clinical Pseudomonas aeruginosa isolates through membrane damage , 2010, FEBS letters.

[15]  C. van Delden,et al.  Lipopolysaccharide as Shield and Receptor for R-Pyocin-Mediated Killing in Pseudomonas aeruginosa , 2010, Journal of bacteriology.

[16]  Steven R. Williams,et al.  An Engineered R-Type Pyocin Is a Highly Specific and Sensitive Bactericidal Agent for the Food-Borne Pathogen Escherichia coli O157:H7 , 2009, Antimicrobial Agents and Chemotherapy.

[17]  M. Cámara,et al.  Quorum sensing and environmental adaptation in Pseudomonas aeruginosa: a tale of regulatory networks and multifunctional signal molecules. , 2009, Current opinion in microbiology.

[18]  Steven R. Williams,et al.  Retargeting R-Type Pyocins To Generate Novel Bactericidal Protein Complexes , 2008, Applied and Environmental Microbiology.

[19]  D. Scholl,et al.  Antibacterial Efficacy of R-Type Pyocins towards Pseudomonas aeruginosa in a Murine Peritonitis Model , 2008, Antimicrobial Agents and Chemotherapy.

[20]  C. Keel,et al.  Biocontrol of Root Diseases by Pseudomonas fluorescens CHA0: Current Concepts and Experimental Approaches , 2007 .

[21]  You-Hee Cho,et al.  R-type pyocin is required for competitive growth advantage between Pseudomonas aeruginosa strains. , 2007, Journal of microbiology and biotechnology.

[22]  Song Jae-Hoon,et al.  Profiling Pyocins and Competitive Growth Advantages of Various Pseudomonas aeruginosa Strains , 2005 .

[23]  Y. Michel-Briand,et al.  The pyocins of Pseudomonas aeruginosa. , 2002, Biochimie.

[24]  H. Mori,et al.  The R‐type pyocin of Pseudomonas aeruginosa is related to P2 phage, and the F‐type is related to lambda phage , 2000, Molecular microbiology.

[25]  S. Lory,et al.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen , 2000, Nature.

[26]  S. Lory,et al.  Complete genome sequence of Pseudomonas aeruginosa PAO 1 , an opportunistic pathogen , 2000 .

[27]  M. Riley,et al.  Molecular mechanisms of bacteriocin evolution. , 1998, Annual review of genetics.

[28]  F. Ausubel,et al.  Common virulence factors for bacterial pathogenicity in plants and animals. , 1995, Science.

[29]  David N. Dowling,et al.  Molecular ecology of rhizosphere microorganisms : biotechnology and the release of GMOs , 1994 .

[30]  M. Kageyama [Pyocins and their genetic determinants]. , 1985, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[31]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[32]  A. Pühler,et al.  A Broad Host Range Mobilization System for In Vivo Genetic Engineering: Transposon Mutagenesis in Gram Negative Bacteria , 1983, Bio/Technology.

[33]  M. Kobayashi,et al.  Characterization of a bacteriophage related to R-type pyocins , 1979, Journal of virology.

[34]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.

[35]  F. Egami,et al.  STUDIES OF A PYOCIN. III. BIOLOGICAL PROPERTIES OF THE PYOCIN. , 1964, Journal of biochemistry.